论文部分内容阅读
目的:研究成人支气管哮喘(简称哮喘)急性发作期不同严重长度哮喘患者血清1-磷酸鞘氨醇(S1P)水平变化,分析其与FEV1的关系,探讨其在哮喘发病中的诊断及治疗价值。方法:以中华医学会呼吸病学分会哮喘学组制定的《中国支气管哮喘防治指南》为指导,将45例哮喘患者分为轻、中、重组,每组15人,采用酶联免疫吸附试验(ELISA)检测每组哮喘患者和25例健康成人血清S1P含量,比较各组血清S1P水平;同时行肺功能检查,采用Pearson法分析各组FEV1% pred与SIP水平的相关性。结果:正常对照组血清S1P水平为(893.2632±175.22495)nmol/L,FEV1%pred为(97.4600±10.44490);哮喘轻度组血清S1P水平为(1519.7500±117.53625)nmol/L,FEV1% pred为(93.2800±9.00390);哮喘中度组血清S1P水平为(1980.8433±176.69450)nmol/L,FEV1% pred为(69.4133±6.606699);哮喘重度组血清S1P水平为(2200.0033±120.94333)nmol/L,FEV1%pred为(42.0933±10.67570)。与健康组相比,哮喘各组血清中S1P水平显著增加(P<0.05);轻、中、重哮喘组患者FEV1%pred、血清SIP水平呈负相关(r值分别为-0.180、-0.177、-0.316),健康对照组患者FEV1% pred与血清SIP水平无相关性(均r=0.48)。结论:各组哮喘患者血清S1P水平随病情严重程度的增加、FEV1% pred的降低而升高。
Objective: To study the changes of serum sphingosine-1-phosphate (S1P) levels in adult asthma patients with acute exacerbation of acute asthma and its relationship with FEV1, and to explore its diagnostic and therapeutic value in the pathogenesis of asthma. Methods: According to “Guidelines for the Prevention and Treatment of Bronchial Asthma in China” developed by the asthma group of the Respiratory Disease Branch of Chinese Medical Association, 45 asthmatic patients were divided into mild, moderate and severe groups with 15 in each group. ELISA was performed using enzyme-linked immunosorbent assay ELISA) was used to detect serum S1P levels in each group of asthmatic patients and 25 healthy adults. Serum levels of S1P in each group were compared. Pulmonary function tests were performed at the same time. Pearson analysis was used to analyze the correlation between FEV1% pred and SIP. Results: Serum S1P level was (893.2632 ± 175.22495) nmol / L and FEV1% pred was (97.4600 ± 10.44490) in normal control group, serum S1P level was (1519.7500 ± 117.53625) nmol / L in mild asthma group, and FEV1% pred was 93.2800 ± 9.00390). Serum levels of S1P in moderate asthma group were (1980.8433 ± 176.69450) nmol / L and FEV1% pred were (69.4133 ± 6.606699) respectively; Serum S1P level was (2200.0033 ± 120.94333) nmol / L and FEV1% pred is (42.0933 ± 10.67570). Serum S1P levels were significantly increased in asthmatic groups compared with healthy controls (P <0.05). FEV1% pred and serum SIP levels were negatively correlated with asthmatic patients (r = -0.180, -0.177, -0.316). There was no correlation between FEV1% pred in healthy controls and serum SIP (all r = 0.48). Conclusion: The serum level of S1P in each asthma group decreased with the increase of FEV1% pred with the severity of the disease.